What To Know
- , a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced new data presentations in peripheral artery disease (PAD) with DCB’s in addition to 12-month AV Registry Data.
- Data presented will cover the use of FLEX Vessel Prep System in both PAD treatment with DCB and also in AV access interventions.
VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced new data presentations in peripheral artery disease (PAD) with DCB’s in addition to 12-month AV Registry Data. These presentations will be given as part of the VEITHsymposium Annual Scientific Meeting 2022. The congress will take place in New York, New York from November 15-19th.
Data presented will cover the use of FLEX Vessel Prep System in both PAD treatment with DCB and also in AV access interventions. The AV Access presentation will expand the 6-month AV Registry data presented at VASA in June with 12-month results.
The two presentations are as follows:
Late Breaking Trial with FLEX Vessel Prep and DCB’s Show Better 12-Month Results With FemPop
Eric A. Secemsky, MD, MSc, RPVI, FACC, FSCAI, FSVM
Director | Vascular Intervention | Beth Israel Deaconess Medical Center
Section Head | Interventional Cardiology and Vascular Research | Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology | Beth Israel Deaconess Medical Center
Assistant Professor of Medicine| Harvard Medical School.
Saturday November 19 6:55am EST
FLEX Vessel Prep System: Clinical Outcomes And Utility In HD Access Practice – AV Registry 12-Month Study Results
John E. Aruny, MD
Primary Investigator,
Dialysis Access Institute,
Orangeburg, SC.
Saturday November 19, 8:22am EST
